海思科公告，公司拟与海利克斯共同投资9700万元设立海思生物科技有限责任公司，其中公司投资8700 万元，持股89.69%；同时共同投资4850万元设立海思新元医药科技有限责任公司，公司投资4350万 元，持股89.69%。 ...

经济观察网佐力药业（300181）近期有多项事件值得关注。公司拟收购资产、发行可转债用于项目建 设，并披露了2025年前三季度的业绩增长情况。 近期事件 公司项目推进 此外，公司于2025年12月披露拟发行不超过15.56亿元可转换公司债券，用于智能化中药大健康工厂等 项目，目前处于推进阶段。 业绩经营情况 根据公开信息，公司于2025年12月15日公告拟以总价3.56亿元收购西藏未来生物医药股份有限公司及其 子公司的资产组，包括多种微量元素注射液系列产品，付款节奏将根据技术资料交接、上市许可变更等 事项分阶段进行。2026年1月15日，公司在机构调研中表示，2026年将加强"院内+院外"双轮驱动，目标 将院外销售占比提升至20%-30%，并推进OTC渠道建设和品牌营销。2026年2月1日，公司举行30周年庆 典，宣布乌灵品牌战略升级，计划通过院内市场夯实和院外拓展，推动"乌灵菌+X"生态布局，目标开 发10个复方制剂并提升C端影响力。 财务方面，2025年1-9月，公司实现营业收入22.80亿元，归母净利润5.10亿元，同比分别增长11.48%和 21.00%。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - The government of Meishan City is promoting six support policies aimed at enhancing the quality and growth of the "1+3" leading industries, with a total of 271 projects approved for support [1]. Group 1: Support Policies - The policies include initiatives for intelligent manufacturing transformation, green low-carbon energy incentives, and high-quality development measures for new energy storage and biomanufacturing industries [1]. - The policies are designed to foster the growth of key sectors such as new energy materials, equipment manufacturing, and pharmaceuticals [1]. Group 2: Project Approval - A total of 271 projects have been evaluated and approved through a process involving voluntary applications from enterprises, recommendations from districts and parks, expert reviews, and on-site verifications [1]. - The projects span various categories, including technological innovation and public service platform construction [2][3]. Group 3: Industry Focus - The focus industries under the "1+3" initiative include new energy materials, pharmaceuticals, and high-end equipment manufacturing [1]. - Specific companies listed for support include Sichuan Qingmu Pharmaceutical Co., Sichuan Tianqi Mining New Energy Technology Co., and Sichuan Jinxiang Saier Chemical Co. [2][3].

Group 1 - The stock price of Yahuang Pharmaceutical-U has shown a downward trend over the past week, with a cumulative decline of 2.67% and a fluctuation of 2.99% [1] - On February 12, the closing price was 12.05 yuan, reflecting a daily decrease of 0.50% [1] - The total trading volume over the past week was approximately 398 million yuan, with an active turnover rate of 1.01% on February 12 [1] Group 2 - The company announced a projected net loss for 2025, with a potential year-on-year increase in losses of 18.00% or a decrease of 1.67% [2] - Expected operating revenue for 2025 is projected to grow by 20.30% to 4.436 billion yuan [2] - Research and development expenses are expected to decrease, with significant progress reported in clinical trials for bladder cancer and ulcerative colitis treatments [2] Group 3 - All institutions have given buy or hold ratings based on data from November and September 2025, indicating a 100% consensus [3] - There have been no significant changes in public sentiment or updates on institutional research and target price information [3]

Group 1 - The core focus events for Dize Pharmaceutical in 2026 and beyond include the progress of H-share listing, key milestones in the R&D pipeline, annual business plan review, and commercialization and market expansion [1] - Dize Pharmaceutical submitted its H-share listing application to the Hong Kong Stock Exchange on January 23, 2026, aiming for a dual listing in Hong Kong to enhance its global strategy and attract international investors [2] - The company plans to advance multiple core products into clinical data update stages in 2026, including the global multi-center Phase III study of Shuwotai (Shuwotai) for EGFR Exon20ins non-small cell lung cancer, which has completed patient enrollment [3] Group 2 - Dize Pharmaceutical plans to hold a board meeting in 2026 to review the annual sales plan, which is yet to be finalized and will be disclosed after board approval [4] - The company aims to leverage the inclusion of core products Shuwotai and Guaizhe in the national medical insurance catalog to deepen domestic market coverage and promote overseas commercialization in 2026 [5] - The sales expense ratio decreased to 72% in the first three quarters of 2025, and the company plans to further enhance operational efficiency in 2026 [5]

同源康医药-B(02410)公布，公司已向联交所上市委员会申请批准公司根据转换公司1名股东持有的460.8 万股非上市股份转换的460.8万股H股上市及买卖经转换H股。联交所已于2026年2月11日授出上市批 准。 ...

Group 1 - The company, Tonghua Golden Horse, has indicated that it will disclose significant information regarding the review of its new drug, Amber Dihydroaminoacridine Tablets, through designated information disclosure media [2] - Investors are advised to pay attention to the company's announcements for updates on the drug's market application review process [2]

Core Viewpoint - The company ST HuLuWa (605199.SH) is facing multiple challenges including expected performance losses, new product approvals, regulatory investigations, and share freezes of its controlling shareholder [1] Group 1: Performance Outlook - The company anticipates a net loss attributable to shareholders in 2025, estimated between -210 million and -310 million yuan, primarily due to industry policy adjustments, market environment changes, increased depreciation from new production facilities, and rising financial costs [2] Group 2: Product Development - The company's wholly-owned subsidiary has received approval from the National Medical Products Administration for the registration of "Compound Polyethylene Glycol Electrolyte Oral Solution," aimed at treating chronic constipation and fecal impaction. Additionally, the company has obtained registration for "Ebastine Oral Solution." These new product approvals are expected to enhance the company's product line, although future sales performance remains uncertain due to policy and market factors [3] Group 3: Regulatory Issues - The company and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, with the investigation ongoing. The company faces risks of investor lawsuits due to prior disclosure issues. Following a negative audit opinion on internal controls for the 2024 financial report, the company's stock has been subject to risk warnings (ST) since April 30, 2025. The company has established a special rectification team to address internal control issues [4] Group 4: Shareholder Pledge - A portion of shares held by the controlling shareholder, Hainan HuLuWa Investment Development Co., Ltd., has been judicially frozen, accounting for 5.97% of the total share capital, which may introduce uncertainties regarding the stability of the company's control [5]

HLX15(即重组抗CD38全人单克隆抗体)是本集团(即本公司及控股子公司/单位,下同)自主研发的达雷妥 尤单抗生物类似药，包括皮下注射剂型HLX15-SC和静脉注射剂型HLX15-IV，拟用于多发性骨髓瘤 (MM)等治疗。2024年6月，在中国男性健康受试者中开展的HLX15-IVⅠ期临床研究已完成。 格隆汇2月12日丨复星医药(600196.SH)公布，公司控股子公司上海复宏汉霖生物技术股份有限公司及其 控股子公司(以下合称"复宏汉霖")收到国家药品监督管理局关于同意HLX15-SC(即重组抗CD38全人单克 隆抗体注射液-皮下注射)用于多发性骨髓瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后在 中国境内(不包括港澳台地区，下同)开展该药品的相关临床研究。 ...

开拓药业-B(09939)发布公告，防脱泡沫剂产品(该产品)为本公司化妆品品牌KOSHIN旗下以KX-826为主 要成分的产品之一。本公司谨此澄清，尽管销售代理协议为进一步推动本公司化妆品商业化提供了有利 机会，但与本集团的上市业务(即本公司核心产品KX-826及GT20029及其他管线产品的开发及商业化) (上市业务)相比，该化妆品销售业务目前规模较小，属辅助性质。谨此说明，该公告所披露的人民币1 亿元销售目标是按累计基准计量的长期目标，而非预期于短期内达致的销售额指标。 人力资源方面，截至本公告日期，在本公司现有的121名雇员中，有69名雇员专门负责药物研发、药物 供应及本地GMP生产，另有24名雇员目前专门负责化妆品销售及本公司候选药物的市场推广及销售准 备。资金方面，根据本公司的管理账目，研发开支预期占本公司截至2025年12月31日止年度开支总额的 50%以上，主要是由于将资金用于KX-826在中国治疗雄激素性脱发(男性)的II期及III期临床研究;及 GT20029在中国治疗痤疮的II期临床研究。 董事已审阅本集团自2025年12月31日起不少于12个月期间的现金流量预测。经考虑(其中包括)本公司 ...